BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 9657073)

  • 1. The effect of GH therapy on the immunoreactive forms and distribution of IGFBP-3, IGF-I, the acid-labile subunit, and growth rate in GH-deficient children.
    Mandel SH; Moreland E; Rosenfeld RG; Gargosky SE
    Endocrine; 1997 Dec; 7(3):351-60. PubMed ID: 9657073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a low molecular mass form of insulin-like growth factor binding protein-3 (17.7 kilodaltons) in urine and serum from healthy children and growth hormone (GH)-deficient patients: relationship with GH therapy.
    Spagnoli A; Gargosky SE; Spadoni GL; MacGillivray M; Oh Y; Boscherini B; Rosenfeld RG
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3668-76. PubMed ID: 8530618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life.
    Aguiar-Oliveira MH; Gill MS; de A Barretto ES; Alcântara MR; Miraki-Moud F; Menezes CA; Souza AH; Martinelli CE; Pereira FA; Salvatori R; Levine MA; Shalet SM; Camacho-Hubner C; Clayton PE
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4118-26. PubMed ID: 10566659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
    Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoblot studies of the acid-labile subunit (ALS) in biological fluids, normal human serum and in children with GH deficiency and GH receptor deficiency before and after long-term therapy with GH or IGF-I respectively.
    Labarta JI; Gargosky SE; Simpson DM; Lee PD; Argente J; Guevara-Aguirre J; Rosenfeld RG
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):657-66. PubMed ID: 9497872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of growth hormone (GH), but not insulin-like growth factor-I (IGF-I), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats.
    Gargosky SE; Tapanainen P; Rosenfeld RG
    Endocrinology; 1994 May; 134(5):2267-76. PubMed ID: 7512499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the ligand immunofunctional assay for human insulin-like growth factor ((IGF) binding protein-3 (IGFBP-3) to analyze IGFBP-3 proteolysis and igf-i bioavailability in healthy adults, GH-deficient and acromegalic patients, and diabetics.
    Lassarre C; Duron F; Binoux M
    J Clin Endocrinol Metab; 2001 May; 86(5):1942-52. PubMed ID: 11344189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collection of blood in heparinized tubes does not alter the molecular distribution or forms of IGFBP-3 and IGF.
    Mandel S; Moreland E; Rosenfeld RG; Gargosky SE
    Endocrine; 1996 Aug; 5(1):1-8. PubMed ID: 21153087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGF-1 Levels, Complex Formation, and IGF Bioactivity in Growth Hormone-Treated Children With Prader-Willi Syndrome.
    Bakker NE; van Doorn J; Renes JS; Donker GH; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3041-9. PubMed ID: 26050733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of the 150-kilodalton insulin-like growth factor-binding protein-3 ternary complex by continuous and pulsatile patterns of growth hormone (GH) administration in GH-deficient patients.
    Laursen T; Flyvbjerg A; Jørgensen JO; Baxter RC; Christiansen JS
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4310-4. PubMed ID: 11095473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in serum growth hormone (GH)/GH dependent ternary complex components (IGF-I, IGFBP-3, ALS, IGF-I/IGFBP-3 molar ratio) and the influence of these alterations on growth pattern in female rhythmic gymnasts.
    Adiyaman P; Ocal G; Berberoğlu M; Evliyaoğlu O; Aycan Z; Cetinkaya E; Bulca Y; Ersöz G; Akar N
    J Pediatr Endocrinol Metab; 2004 Jun; 17(6):895-903. PubMed ID: 15270408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The composition and distribution of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: effects of IGF-I therapy on IGFBP-3.
    Gargosky SE; Wilson KF; Fielder PJ; Vaccarello MA; Guevara-Aguirre J; Diamond FB; Baxter RC; Rosenbloom AL; Rosenfeld RG
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1683-9. PubMed ID: 7505289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The GH-IGF-IGFBP axis is changed in Turner syndrome: partial normalization by HRT.
    Gravholt CH; Chen JW; Oxvig C; Overgaard MT; Christiansen JS; Frystyk J; Flyvbjerg A
    Growth Horm IGF Res; 2006; 16(5-6):332-9. PubMed ID: 17067837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inaccuracy of insulin-like growth factor (IGF) binding protein (IGFBP)-3 assessment in the diagnosis of growth hormone (GH) deficiency from childhood to young adulthood: association to low GH dependency of IGF-II and presence of circulating IGFBP-3 18-kilodalton fragment.
    Cianfarani S; Liguori A; Boemi S; Maghnie M; Iughetti L; Wasniewska M; Street ME; Zucchini S; Aimaretti G; Germani D
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6028-34. PubMed ID: 16091488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in insulin-like growth factor-I (IGF-I), IGF-binding protein-3, growth hormone (GH)-binding protein, erythrocyte IGF-I receptors, and growth rate during GH treatment.
    Mandel S; Moreland E; Nichols V; Hanna C; Lafranchi S
    J Clin Endocrinol Metab; 1995 Jan; 80(1):190-4. PubMed ID: 7530256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency.
    Juul A; Møller S; Mosfeldt-Laursen E; Rasmussen MH; Scheike T; Pedersen SA; Kastrup KW; Yu H; Mistry J; Rasmussen S; Müller J; Henriksen J; Skakkebaek NE
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4408-15. PubMed ID: 9851786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acid-labile subunit in growth hormone excess and deficiency in adults: evaluation of its diagnostic value in comparison with insulin-like growth factor (IGF)-I and IGF-binding protein-3.
    Fukuda I; Hizuka N; Itoh E; Yasumoto K; Ishikawa Y; Murakami Y; Sata A; Takano K
    Endocr J; 2002 Jun; 49(3):379-86. PubMed ID: 12201224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.